Earnings calls

Tarsons Products concall ledger

Every earnings call for TARSONS — management tone, guidance, KPIs and promise tracking, quarter by quarter.

TARSONS · 4 transcripts · Healthcare · latest Q3 FY26

Q3 FY26Published 06 Feb 2026Call held 06 Feb 2026

TARSONS Q3 FY26 Earnings Call Transcript & Analysis

Consolidated Revenue₹108 cr+13% YoYConsolidated EBITDA₹31.5 crConsolidated EBITDA Margin29.2%

Consolidated Revenue ₹108 cr (+13% YoY); Consolidated EBITDA ₹32 cr; Consolidated EBITDA Margin 29.2%. Consolidated revenue grew 12.8% YoY to INR 108 crores in Q3 FY26.

Read full transcript & analysis

Q2 FY26Published 13 Nov 2025Call held 13 Nov 2025

TARSONS Q2 FY26 Earnings Call Transcript & Analysis

Standalone Revenue₹81 crStandalone EBITDA₹26 cr+11% YoYStandalone EBITDA Margin32.5%Standalone PAT₹6.5 cr−50% YoY

Standalone Revenue ₹81 cr; Standalone EBITDA ₹26 cr (+11% YoY); Standalone EBITDA Margin 32.5%. Q2 FY26 Standalone EBITDA of ₹26 crores, up 11% YoY.

Read full transcript & analysis

Q1 FY26Published 12 Aug 2025Call held 12 Aug 2025

TARSONS Q1 FY26 Earnings Call Transcript & Analysis

Consolidated Revenue₹91 cr+8% YoYConsolidated EBITDA₹25 crStandalone EBITDA Margin31.2%Consolidated PAT₹1.8 cr

Consolidated Revenue ₹91 cr (+8% YoY); Consolidated EBITDA ₹25 cr; Standalone EBITDA Margin 31.2%. Consolidated revenue grew 8% YoY to INR 91 crores.

Read full transcript & analysis

Q4 FY25Published 29 May 2025Call held 29 May 2025

TARSONS Q4 FY25 Earnings Call Transcript & Analysis

Consolidated Revenue₹113 cr+7% YoYConsolidated EBITDA₹37 cr+22% YoYConsolidated EBITDA Margin32.9%Standalone PAT₹16 cr

Consolidated Revenue ₹113 cr (+7% YoY); Consolidated EBITDA ₹37 cr (+22% YoY); Consolidated EBITDA Margin 32.9%. Consolidated revenues grew 7% YoY in Q4 FY25 to INR 113 crores.

Read full transcript & analysis